Newsfeeds Archive - Page 2 of 64

2 minute read

AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability

June 7, 10:39 AM

Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.

ABBV

2 minute read

Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial

By Benzinga Neuro

June 4, 1:58 AM

The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged bankruptcy.

JNJ

1 minute read

Johnson & Johnson Announces Results From A Subgroup Analysis Of The Phase 3 CARTITUDE-4 Study Showing CARVYKTI Improved Progression-Free Survival And Deepened Responses Versus Two Standard Therapies For Patients With Functional High-Risk Multiple Myelo…

By Benzinga Newsdesk

June 3, 3:58 PM

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1CHICAGO, June 3, 2024

JNJ

1 minute read

Johnson & Johnson Announces Data From Phase 3 PERSEUS Study Showing DARZALEX-Based Regimens Significantly Improve Clinical Outcomes In Both Transplant-Eligible And -Ineligible Patients Who Are Newly Diagnosed With Multiple Myeloma

By Benzinga Newsdesk

June 3, 3:51 PM

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and

JNJ

1 minute read

Johnson & Johnson’s Late-Breaking Results From Its PALOMA-2 Study Of Subcutaneous Amivantamab In Combination With Lazertinib Show Clinically Meaningful Antitumor Response And Improved Safety Profile In Patients With EGFR-Mutated Non-Small Cell Lung Can…

By Benzinga Newsdesk

June 3, 2:33 PM

administration in new Phase 2 dataCHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as

JNJ

2 minute read

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients

By Vandana Singh

June 3, 12:01 PM

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.

JNJ

3 minute read

Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry

By Benzinga Insights

June 3, 11:00 AM

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry…

JNJ

1 minute read

Movers
News

Why Sarepta Therapeutics Stock Is Rising Today

By Dylan Berman

May 30, 2:20 PM

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

JNJ

2 minute read

Johnson & Johnson’s Drug Seltorexant Aces Late-Stage Depression Trial

By Vandana Singh

May 29, 12:55 PM

Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia.

JNJ

1 minute read

Johnson & Johnson Pivotal Study Of Seltorexant Shows Clinically Meaningful Improvement In Depressive Symptoms And Sleep Disturbance Outcomes

By Benzinga Newsdesk

May 29, 12:18 PM

https://www.jnj.com/media-center/press-releases/johnson-johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes&nbs

JNJ